Currently, zenocutuzumab is designated as an orphan drug for pancreatic ductal adenocarcinoma and is on a fast-track approval process for use as standard therapy in advanced NRG1+ cancers. This evidence concerns the gene NRG1 and pancreatic ductal adenocarcinoma.